房颤患者达比加群治疗2年持续性研究
该研究随访2932例新诊断房颤且至少有一个卒中危险因素的患者,评估达比加群2年治疗持续性。2年持续用药概率为69.2%,约7%换用Xa抑制剂、6%换用维生素K拮抗剂,近三分之一停药主要因不良事件。北美患者停药风险最高,拉丁美洲最低。
要点
- 达比加群2年持续用药概率约69.2%,近半数停药者换用其他口服抗凝药。
- 约三分之一停药主要因严重或非严重不良事件。
- 北美患者停药风险最高,拉丁美洲最低;阵发性/持续性/症状性房颤停药风险更高。
核心结论
- 达比加群治疗2年后持续用药概率约为70%。
- 停药患者中近一半换用其他口服抗凝药。
- 北美患者及阵发性、持续性或症状性房颤患者停药风险可能更高。
研究设计与样本
- 研究纳入连续新诊断房颤且至少有一个卒中危险因素的患者,随访2年。
- 达比加群不持续定义为停药超过30天。
- 采用多变量Cox回归模型分析不持续的预测因素,纳入地区、临床和社会人口学特征。
- eligible患者N=2932,至少服用一剂达比加群,平均年龄70.3±10.2岁,男性占55.3%。
主要发现
- 2年达比加群持续概率为69.2%。
- 约7%换用Xa抑制剂,6%换用VKA。
- 约三分之一停药主要因严重或非严重不良事件。
- 北美患者停药风险最高,拉丁美洲最低。
- 轻微症状或无症状房颤及永久性房颤与较低的不持续风险相关。
临床怎么用
- 对新诊断房颤患者启动达比加群时,应关注2年内约30%的停药风险。
- 停药后近半数患者换用其他口服抗凝药,需及时调整抗凝方案。
- 北美地区、阵发性/持续性/症状性房颤及既往PPI使用患者需加强随访和依从性管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend long-term oral anticoagulation therapy for stroke prevention in patients with atrial fibrillation (AF). Treatment discontinuation rates in vitamin K antagonist (VKA)-treated patients are high but may be lower with non-VKA oral anticoagulant agents. OBJECTIVES: The goal of this study was to describe and explore predictors of dabigatran etexilate persistence in patients with newly diagnosed AF over 2 years of follow-up. METHODS: Consecutive patients newly diagnosed with AF and ≥1 stroke risk factor were followed up for 2 years. Dabigatran nonpersistence was defined as discontinuation of dabigatran for >30 days. A multivariable Cox regression model included region as well as patient clinical and sociodemographic characteristics to explore predictors of nonpersistence. RESULTS: Eligible patients (N = 2,932) took ≥1 dabigatran dose; their mean age was 70.3 ± 10.2 years, and 55.3% were male. The 2-year probability of dabigatran persistence was 69.2%. Approximately 7% switched to a factor Xa inhibitor and 6% to a VKA. Approximately one-third of dabigatran discontinuations were primarily due to serious or nonserious adverse events. Patients from North America had the highest discontinuation risk, and Latin America had the lowest. Minimally symptomatic or asymptomatic AF and permanent AF were associated with a lower risk for dabigatran nonpersistence. Previous proton pump inhibitor use was associated with a higher risk for dabigatran nonpersistence. CONCLUSIONS: Probability of treatment persistence with dabigatran after 2 years was approximately 70%. Nearly one-half of the patients who stopped dabigatran switched to another oral anticoagulant agent. Patients from North America, and those with paroxysmal, persistent, or symptomatic AF, may be at a higher risk for discontinuing dabigatran.
引用
- Paquette M, Riou França L, Teutsch C, et al. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017. PMID: 28935034. doi:10.1016/j.jacc.2017.07.793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。